Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Altimmune, Inc.NASDAQ: ALT

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses growth accelerates

Q1 FY2026 other income / expenses of $1.68M rose 7.8% year over year, ahead of the -19.7% change in trailing-twelve-month other income / expenses. Sequentially, it rose 9.5% from the prior quarter. Over 3 fiscal years it compounded at +26.4% a year.

Context

  • Other income / expenses amounted to 13939.0% of revenue in FY2025, down 26626.0 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +7.8% holds above the trailing-twelve-month pace of -19.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.68M+9.5% QoQ
Last fiscal yearDec 2025
$5.72M-29.6% YoY
LTMMar 2026
$5.84M-19.7% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.8%——
1 year-29.6%——
3-year CAGR+26.4%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
5.72M USD
Year-over-year change
-29.6%

Other Income / Expenses vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.7% is the 4th highest of 9, against a peer median of -65.6%.
  • Other income / expenses amounts to 16213.9% of revenue for ALT, versus a peer median of 10.1%.
ALT Competitors
Other Income / Expenses for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$43.71M USD+6.2%+388.5%—
BMEABiomea Fusion, Inc.LTM Mar 2026$21.62M USD+427.9%+121.1%—
VIRVir Biotechnology, Inc.LTM Mar 2026$19.31M USD-71.4%—29.5%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$7.16M USD+37.9%+80.4%10.1%
ABUSArbutus Biopharma CorporationLTM Mar 2026$6.05M USD-59.8%—3.2%
ALTAltimmune, Inc.LTM Mar 2026$5.84M USD-19.7%+26.4%16213.9%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026-$1.44M USD-681.1%——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$1.51M USD-146.9%+2.8%2.2%
IVAInventiva S.A.FY2025-€211.38M EUR-144.8%—4715.1%
Peer median (excluding ALT) —-65.6%+100.7%10.1%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.